Luminity (perflutren)
- Region
- 🇪🇺 EU
- Active substance
- perflutren
- Company
- Lantheus EU Limited
- Status
- Authorised
- Therapeutic area
- Echocardiography
- CHMP opinion
- Thu 27 Jul 2006
- EU approval
- Wed 20 Sep 2006
- Application
- EMEA/H/C/000654
- ATC
- V08DA04
- Official record
- www.ema.europa.eu
Indication
This medicinal product is for diagnostic use only. Luminity is an ultrasound contrast-enhancing agent for use in patients in whom non-contrast echocardiography was suboptimal (suboptimal is considered to indicate that at least two of six segments in the 4- or 2-chamber view of the ventricular border were not evaluable) and who have suspected or established coronary artery disease, to provide opacification of cardiac chambers and improvement of left ventricular endocardial border delineation at both rest and stress.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Optison Authorised · GE Healthcare AS
Follow Luminity
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.